BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Innate Pharma SA

Ouvert

1.748 -0.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.74

Max

1.77

Chiffres clés

By Trading Economics

Revenu

-25M

Ventes

12M

Marge bénéficiaire

-200.599

Employés

181

EBITDA

-26M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+144.33% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

144M

Ouverture précédente

2.43

Clôture précédente

1.748

Score Technique

By Trading Central

Confiance

Bullish Evidence

Innate Pharma SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Intel, AppFolio

24 avr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 avr. 2025, 23:37 UTC

Actualités

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 avr. 2025, 23:36 UTC

Actualités

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 avr. 2025, 23:13 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 avr. 2025, 23:09 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 avr. 2025, 22:51 UTC

Actualités
Acquisitions, Fusions, Rachats

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 avr. 2025, 22:48 UTC

Actualités

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 avr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 avr. 2025, 22:38 UTC

Market Talk
Résultats

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 avr. 2025, 22:24 UTC

Market Talk
Résultats

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 avr. 2025, 22:23 UTC

Résultats

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 avr. 2025, 22:09 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 avr. 2025, 22:00 UTC

Market Talk
Résultats

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 avr. 2025, 21:39 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 avr. 2025, 21:23 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 avr. 2025, 21:04 UTC

Résultats

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 avr. 2025, 21:02 UTC

Résultats

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparaison

Variation de prix

Innate Pharma SA prévision

Objectif de Prix

By TipRanks

144.33% hausse

Prévisions sur 12 Mois

Moyen 4.398 EUR  144.33%

Haut 5.7 EUR

Bas 3.1 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.736 / 1.776Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.